These findings provide insights into the role of HLA-DRB1*11 genetic testing in differentiating non-immune muscle toxicity from anti-HMGCR IMNM in patients receiving statins, particularly in settings where autoantibody testing for inflammatory myopathies, skeletal muscle biopsy is unavailable, or conclusive diagnostic studies are obtained. The gene discussed is HMGCR; the disease is myopathy.